We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+39.83%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.49B
AUM Growth
-$20.6M
Cap. Flow
-$290M
Cap. Flow %
-19.48%
Top 10 Hldgs %
73.48%
Holding
39
New
4
Increased
5
Reduced
23
Closed
–

Top Buys

Rank Stock Value
1
AGMB
AgomAb Therapeutics NV
AGMB
+$29M
2
CLYM
Climb Bio
CLYM
+$12.7M
3
AURA icon
Aura Biosciences
AURA
+$11.9M
4
STTK icon
Shattuck Labs
STTK
+$8.43M
5
ODTX
Odyssey Therapeutics
ODTX
+$7.45M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$230M
2
NRIX icon
Nurix Therapeutics
NRIX
+$62.3M
3
ANNX icon
Annexon
ANNX
+$14.8M
4
IMNM icon
Immunome
IMNM
+$13.9M
5
KRYS icon
Krystal Biotech
KRYS
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

1 2

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2026 Portfolio in Review

As of Q2 2026, Redmile Group held 39 positions worth $1.49B, down 1.4% from $1.51B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Redmile Group withdrew a net $290M in Q2 2026, reducing 23 holdings. Its largest reduction was Scholar Rock, cutting an estimated $230M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Redmile Group opened a new position in Climb Bio worth $16M.

  • Redmile Group's largest Q2 2026 buy was Climb Bio: 1,226,330 shares worth $16M.
  • Redmile Group added most to AgomAb Therapeutics NV in Q2 2026, an estimated $29M increase.
  • Redmile Group's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $230M.
  • Redmile Group's ten largest holdings make up 73% of its $1.49B portfolio in Q2 2026.
  • Redmile Group opened 4 new positions and closed 0 in Q2 2026.
  • Redmile Group's portfolio value fell 1.4% quarter-over-quarter to $1.49B.

Based on Redmile Group's 13F filing for Q2 2026, filed 14 Aug 2026.